The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cancer Tumor Profiling-Global Market Insights and Sales Trends 2025
Synopsis
Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.
The global Cancer Tumor Profiling market size is expected to reach US$ 81350 million by 2029, growing at a CAGR of 10.4% from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Tumor Profiling in various end use industries. The expanding demands from the Personalized Medicine, Diagnostics, Biomarker Discovery and Prognostics, are propelling Cancer Tumor Profiling market. Next-generation Sequencing (NGS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Polymerase Chain Reaction (PCR) segment is estimated at % CAGR for the next seven-year period.
The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Tumor Profiling, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Tumor Profiling market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Tumor Profiling market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Tumor Profiling sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Tumor Profiling covered in this report include Qiagen N.V., Roche Molecular Systems Inc., Abott Molecular, Illumina Inc., NeoGenomics Laboratories, HTG Molecular Diagnostic, Genomic Health Inc., Hologic Gen-Probe and BD Biosciences, etc.
The global Cancer Tumor Profiling market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Qiagen N.V.
Roche Molecular Systems Inc.
Abott Molecular
Illumina Inc.
NeoGenomics Laboratories
HTG Molecular Diagnostic
Genomic Health Inc.
Hologic Gen-Probe
BD Biosciences
Siemens Healthineers
Claris Life Sciences
Personal Genome Diagnostics, Inc.
Perthera, Inc.
Foundation Medicine, Inc
V., Strand
ApoCell
Contextual Genomics
Agendia
GenScript
Global Cancer Tumor Profiling market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Tumor Profiling market, Segment by Type:
Next-generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Microarray
Others
Global Cancer Tumor Profiling market, by Application
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Research Applications
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Tumor Profiling companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Cancer/tumor profiling provides information about the genes causing cancer, which would offer useful insights related to the mechanism of cancer. The potential of cancer profiling is not only limited to common cancers, such as lymphoma and breast cancer, but also is useful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has plays a vital role in diagnosis at the molecular level, as better understanding of the cancer tumors helps physicians to make appropriate therapeutic decisions and avoid “over-treatment” of the cancer patients.
The global Cancer Tumor Profiling market size is expected to reach US$ 81350 million by 2029, growing at a CAGR of 10.4% from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Tumor Profiling in various end use industries. The expanding demands from the Personalized Medicine, Diagnostics, Biomarker Discovery and Prognostics, are propelling Cancer Tumor Profiling market. Next-generation Sequencing (NGS), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Polymerase Chain Reaction (PCR) segment is estimated at % CAGR for the next seven-year period.
The global market is driven by growing demand for cancer profiling method by oncologists to diagnose or treat cancers as well as predict response to targeted therapy. In addition, rise in adoption of cancer biomarkers for tumor profiling, increase in incidence of cancer across the globe, and growth in use of next-generation sequencing technique for cancer profiling boost the market growth. However, high monetary investments for the development of biomarkers and dearth of skilled professionals or oncologists specific to tumor profiling hamper the market growth.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Tumor Profiling, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Tumor Profiling market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Tumor Profiling market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Tumor Profiling sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Tumor Profiling covered in this report include Qiagen N.V., Roche Molecular Systems Inc., Abott Molecular, Illumina Inc., NeoGenomics Laboratories, HTG Molecular Diagnostic, Genomic Health Inc., Hologic Gen-Probe and BD Biosciences, etc.
The global Cancer Tumor Profiling market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Qiagen N.V.
Roche Molecular Systems Inc.
Abott Molecular
Illumina Inc.
NeoGenomics Laboratories
HTG Molecular Diagnostic
Genomic Health Inc.
Hologic Gen-Probe
BD Biosciences
Siemens Healthineers
Claris Life Sciences
Personal Genome Diagnostics, Inc.
Perthera, Inc.
Foundation Medicine, Inc
V., Strand
ApoCell
Contextual Genomics
Agendia
GenScript
Global Cancer Tumor Profiling market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Tumor Profiling market, Segment by Type:
Next-generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In Situ Hybridization (ISH)
Microarray
Others
Global Cancer Tumor Profiling market, by Application
Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Research Applications
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Tumor Profiling companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cancer Tumor Profiling
1.1 Cancer Tumor Profiling Market Overview
1.1.1 Cancer Tumor Profiling Product Scope
1.1.2 Cancer Tumor Profiling Market Status and Outlook
1.2 Global Cancer Tumor Profiling Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cancer Tumor Profiling Market Size by Region (2018-2029)
1.4 Global Cancer Tumor Profiling Historic Market Size by Region (2018-2023)
1.5 Global Cancer Tumor Profiling Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cancer Tumor Profiling Market Size (2018-2029)
1.6.1 North America Cancer Tumor Profiling Market Size (2018-2029)
1.6.2 Europe Cancer Tumor Profiling Market Size (2018-2029)
1.6.3 Asia-Pacific Cancer Tumor Profiling Market Size (2018-2029)
1.6.4 Latin America Cancer Tumor Profiling Market Size (2018-2029)
1.6.5 Middle East & Africa Cancer Tumor Profiling Market Size (2018-2029)
2 Cancer Tumor Profiling Market by Type
2.1 Introduction
2.1.1 Next-generation Sequencing (NGS)
2.1.2 Polymerase Chain Reaction (PCR)
2.1.3 Immunohistochemistry (IHC)
2.1.4 In Situ Hybridization (ISH)
2.1.5 Microarray
2.1.6 Others
2.2 Global Cancer Tumor Profiling Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cancer Tumor Profiling Historic Market Size by Type (2018-2023)
2.2.2 Global Cancer Tumor Profiling Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cancer Tumor Profiling Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cancer Tumor Profiling Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cancer Tumor Profiling Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cancer Tumor Profiling Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cancer Tumor Profiling Revenue Breakdown by Type (2018-2029)
3 Cancer Tumor Profiling Market Overview by Application
3.1 Introduction
3.1.1 Personalized Medicine
3.1.2 Diagnostics
3.1.3 Biomarker Discovery
3.1.4 Prognostics
3.1.5 Research Applications
3.2 Global Cancer Tumor Profiling Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cancer Tumor Profiling Historic Market Size by Application (2018-2023)
3.2.2 Global Cancer Tumor Profiling Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cancer Tumor Profiling Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cancer Tumor Profiling Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cancer Tumor Profiling Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cancer Tumor Profiling Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cancer Tumor Profiling Revenue Breakdown by Application (2018-2029)
4 Cancer Tumor Profiling Competition Analysis by Players
4.1 Global Cancer Tumor Profiling Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Tumor Profiling as of 2022)
4.3 Date of Key Players Enter into Cancer Tumor Profiling Market
4.4 Global Top Players Cancer Tumor Profiling Headquarters and Area Served
4.5 Key Players Cancer Tumor Profiling Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer Tumor Profiling Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Qiagen N.V.
5.1.1 Qiagen N.V. Profile
5.1.2 Qiagen N.V. Main Business
5.1.3 Qiagen N.V. Cancer Tumor Profiling Products, Services and Solutions
5.1.4 Qiagen N.V. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.1.5 Qiagen N.V. Recent Developments
5.2 Roche Molecular Systems Inc.
5.2.1 Roche Molecular Systems Inc. Profile
5.2.2 Roche Molecular Systems Inc. Main Business
5.2.3 Roche Molecular Systems Inc. Cancer Tumor Profiling Products, Services and Solutions
5.2.4 Roche Molecular Systems Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Molecular Systems Inc. Recent Developments
5.3 Abott Molecular
5.3.1 Abott Molecular Profile
5.3.2 Abott Molecular Main Business
5.3.3 Abott Molecular Cancer Tumor Profiling Products, Services and Solutions
5.3.4 Abott Molecular Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.3.5 Illumina Inc. Recent Developments
5.4 Illumina Inc.
5.4.1 Illumina Inc. Profile
5.4.2 Illumina Inc. Main Business
5.4.3 Illumina Inc. Cancer Tumor Profiling Products, Services and Solutions
5.4.4 Illumina Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.4.5 Illumina Inc. Recent Developments
5.5 NeoGenomics Laboratories
5.5.1 NeoGenomics Laboratories Profile
5.5.2 NeoGenomics Laboratories Main Business
5.5.3 NeoGenomics Laboratories Cancer Tumor Profiling Products, Services and Solutions
5.5.4 NeoGenomics Laboratories Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.5.5 NeoGenomics Laboratories Recent Developments
5.6 HTG Molecular Diagnostic
5.6.1 HTG Molecular Diagnostic Profile
5.6.2 HTG Molecular Diagnostic Main Business
5.6.3 HTG Molecular Diagnostic Cancer Tumor Profiling Products, Services and Solutions
5.6.4 HTG Molecular Diagnostic Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.6.5 HTG Molecular Diagnostic Recent Developments
5.7 Genomic Health Inc.
5.7.1 Genomic Health Inc. Profile
5.7.2 Genomic Health Inc. Main Business
5.7.3 Genomic Health Inc. Cancer Tumor Profiling Products, Services and Solutions
5.7.4 Genomic Health Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.7.5 Genomic Health Inc. Recent Developments
5.8 Hologic Gen-Probe
5.8.1 Hologic Gen-Probe Profile
5.8.2 Hologic Gen-Probe Main Business
5.8.3 Hologic Gen-Probe Cancer Tumor Profiling Products, Services and Solutions
5.8.4 Hologic Gen-Probe Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.8.5 Hologic Gen-Probe Recent Developments
5.9 BD Biosciences
5.9.1 BD Biosciences Profile
5.9.2 BD Biosciences Main Business
5.9.3 BD Biosciences Cancer Tumor Profiling Products, Services and Solutions
5.9.4 BD Biosciences Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.9.5 BD Biosciences Recent Developments
5.10 Siemens Healthineers
5.10.1 Siemens Healthineers Profile
5.10.2 Siemens Healthineers Main Business
5.10.3 Siemens Healthineers Cancer Tumor Profiling Products, Services and Solutions
5.10.4 Siemens Healthineers Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.10.5 Siemens Healthineers Recent Developments
5.11 Claris Life Sciences
5.11.1 Claris Life Sciences Profile
5.11.2 Claris Life Sciences Main Business
5.11.3 Claris Life Sciences Cancer Tumor Profiling Products, Services and Solutions
5.11.4 Claris Life Sciences Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.11.5 Claris Life Sciences Recent Developments
5.12 Personal Genome Diagnostics, Inc.
5.12.1 Personal Genome Diagnostics, Inc. Profile
5.12.2 Personal Genome Diagnostics, Inc. Main Business
5.12.3 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Products, Services and Solutions
5.12.4 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.12.5 Personal Genome Diagnostics, Inc. Recent Developments
5.13 Perthera, Inc.
5.13.1 Perthera, Inc. Profile
5.13.2 Perthera, Inc. Main Business
5.13.3 Perthera, Inc. Cancer Tumor Profiling Products, Services and Solutions
5.13.4 Perthera, Inc. Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.13.5 Perthera, Inc. Recent Developments
5.14 Foundation Medicine, Inc
5.14.1 Foundation Medicine, Inc Profile
5.14.2 Foundation Medicine, Inc Main Business
5.14.3 Foundation Medicine, Inc Cancer Tumor Profiling Products, Services and Solutions
5.14.4 Foundation Medicine, Inc Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.14.5 Foundation Medicine, Inc Recent Developments
5.15 V., Strand
5.15.1 V., Strand Profile
5.15.2 V., Strand Main Business
5.15.3 V., Strand Cancer Tumor Profiling Products, Services and Solutions
5.15.4 V., Strand Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.15.5 V., Strand Recent Developments
5.16 ApoCell
5.16.1 ApoCell Profile
5.16.2 ApoCell Main Business
5.16.3 ApoCell Cancer Tumor Profiling Products, Services and Solutions
5.16.4 ApoCell Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.16.5 ApoCell Recent Developments
5.17 Contextual Genomics
5.17.1 Contextual Genomics Profile
5.17.2 Contextual Genomics Main Business
5.17.3 Contextual Genomics Cancer Tumor Profiling Products, Services and Solutions
5.17.4 Contextual Genomics Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.17.5 Contextual Genomics Recent Developments
5.18 Agendia
5.18.1 Agendia Profile
5.18.2 Agendia Main Business
5.18.3 Agendia Cancer Tumor Profiling Products, Services and Solutions
5.18.4 Agendia Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.18.5 Agendia Recent Developments
5.19 GenScript
5.19.1 GenScript Profile
5.19.2 GenScript Main Business
5.19.3 GenScript Cancer Tumor Profiling Products, Services and Solutions
5.19.4 GenScript Cancer Tumor Profiling Revenue (US$ Million) & (2018-2023)
5.19.5 GenScript Recent Developments
6 North America
6.1 North America Cancer Tumor Profiling Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cancer Tumor Profiling Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer Tumor Profiling Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer Tumor Profiling Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer Tumor Profiling Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer Tumor Profiling Market Dynamics
11.1 Cancer Tumor Profiling Industry Trends
11.2 Cancer Tumor Profiling Market Drivers
11.3 Cancer Tumor Profiling Market Challenges
11.4 Cancer Tumor Profiling Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
